Article (Scientific journals)
Le medicament du mois. La rosiglitazone (Avandia).
Scheen, André
2002In Revue Médicale de Liège, 57 (4), p. 236-9
Peer reviewed
 

Files


Full Text
200204_12.pdf
Publisher postprint (450.66 kB)
Download

All documents in ORBi are protected by a user license.

Send to



Details



Keywords :
Administration, Oral; Diabetes Mellitus, Type 2/drug therapy; Heart Failure; Humans; Hypoglycemic Agents/administration & dosage/adverse effects/pharmacology; Insulin/pharmacology; Insulin Resistance; Liver/drug effects/pathology; Prognosis; Risk Factors; Thiazoles/administration & dosage/adverse effects/pharmacology; Thiazolidinediones; Weight Gain
Abstract :
[en] Rosiglitazone (Avandia, Glaxo-SmithKline) belongs to a new family of oral hypoglycaemic agents, thiazolidinediones or glitazones. These molecules act as selective agonists of nuclear receptors (PPAR gamma) and improve insulin sensitivity. In Belgium as in all European countries, rosiglitazone is indicated for the treatment of type 2 diabetes, only in combination with another antidiabetic oral agent, in patients insufficiently controlled with metformin or a sulphonylurea at a maximal tolerated dose. In these patients, rosiglitazone, at a daily dose of 4 mg (sometimes 8 mg/day with metformin), reduces fasting glycaemia by 2-3 mmol/l and glycated haemoglobin level by about 1%. It exerts also favourable effects on some risk factors related to insulin resistance syndrome, which may contribute to improve cardiovascular prognosis of patients with type 2 diabetes. Hepatic safety of rosiglitazone seems to be good, although it is still recommended to check liver enzymes regularly. As all glitazones, rosiglitazone moderately promotes weight gain. It can also induce some fluid retention which may reveal or aggravate heart failure in at risk patients.
Disciplines :
Pharmacy, pharmacology & toxicology
Endocrinology, metabolism & nutrition
Author, co-author :
Scheen, André  ;  Université de Liège - ULiège > Département des sciences cliniques > Diabétologie, nutrition et maladie métaboliques - Médecine interne générale
Language :
French
Title :
Le medicament du mois. La rosiglitazone (Avandia).
Alternative titles :
[en] Medication of the month. Rosiglitazone (Avandia)
Publication date :
2002
Journal title :
Revue Médicale de Liège
ISSN :
0370-629X
eISSN :
2566-1566
Publisher :
Université de Liège. Revue Médicale de Liège, Liège, Belgium
Volume :
57
Issue :
4
Pages :
236-9
Peer reviewed :
Peer reviewed
Additional URL :
Available on ORBi :
since 08 April 2009

Statistics


Number of views
172 (0 by ULiège)
Number of downloads
157 (0 by ULiège)

Scopus citations®
 
9
Scopus citations®
without self-citations
4

Bibliography


Similar publications



Contact ORBi